title: Fenofibrate and Diabetic Retinopathy.
abstract: Diabetic retinopathy, a common and sight-threatening microvascular complication of diabetes mellitus, is a leading cause of blindness among working-aged adults. Medical therapies including intensive control of hyperglycemia and hypertension have been shown to reduce the incidence and progression of diabetic retinopathy. The association of dyslipidemia and treatment with statins with diabetic retinopathy is inconsistent in epidemiologic studies. However, two recent randomized clinical trials have demonstrated beneficial effects of systemic fenofibrate therapy in reducing the progression of diabetic retinopathy independently of serum lipid levels. These findings suggest that fenofibrate may be an effective strategy for reducing the progression of diabetic retinopathy, thus reducing the large and growing public health burden of treating the sight-threatening complications of diabetic retinopathy.
authors.affiliation: National Eye Institute, National Institutes of Health, 10 Center Dr, 10/10D45, Bethesda, MD, 20892, USA.
authors.forename: Jared E
authors.initials: JE
authors.lastname: Knickelbein
authors.affiliation: National Eye Institute, National Institutes of Health, 10 Center Dr, 10/10D45, Bethesda, MD, 20892, USA.
authors.forename: Akshar B
authors.initials: AB
authors.lastname: Abbott
authors.affiliation: National Eye Institute, National Institutes of Health, 10 Center Dr, 10/10D45, Bethesda, MD, 20892, USA. echew@nei.nih.gov.|Division of Epidemiology and Clinical Applications, Clinical Trials Branch, National Eye Institute/National Institutes of Health, Bldg 10-Clinical Research Center, Room 3-2531, 10 Center Dr, Mailstop Code 1204, Bethesda, MD, 20892, USA. echew@nei.nih.gov.
authors.forename: Emily Y
authors.initials: EY
authors.lastname: Chew
mesh_terms: D003930:Diabetic Retinopathy / Q000188:drug therapy*; D050171:Dyslipidemias / Q000188:drug therapy; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D011345:Fenofibrate
keywords: Diabetic macular edema; Diabetic retinopathy; Fenofibrate